Jennifer Clough

Jennifer Clough

Auto-generated profile, based on publicly available information

Jennifer Clough

Exeter IBD Research Group, University of Exeter Exeter IBD and Pharmacogenetics Research Group, Exeter, Devon, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2020 in Gut
Verified
Journal Article
Open access
PDF file
JCJennie N Clough
Jennie N Clough
OOOmer S Omer
Omer S Omer
STScott Tasker
Scott Tasker
GLGraham MIchael Lord
Graham MIchael Lord
PIPeter M Irving
Peter M Irving
The prevalence of IBD is rising in the Western world. Despite an increasing repertoire of therapeutic targets, a significant proportion of patients suffer chronic morbidity. Studies in mice and humans have highlighted the critical role of regulatory T cells in immune homeostasis, with defects in number and suppressive function of regulatory T cells seen in patients with Crohn’s disease. We review the function of regulatory T cells and the pathways by which they exert immune tolerance in the intestinal mucosa. We explore the principles and challenges of manufacturing a cell therapy, and discuss clinical trial evidence to date for their safety and efficacy in human disease, with particular focus on the development of a regulatory T-cell therapy for Crohn’s disease.

5 March 2019 in Frontline Gastroenterology
Verified
Journal Article
Closed access
PDF file
JCJennifer Clough
Jennifer Clough
MFMichael FitzPatrick
Michael FitzPatrick
PHPhilip Harvey
Philip Harvey
LMLiam Morris
Liam Morris
Background Physician training in the UK is undergoing considerable change due to the implementation of recommendations made in the Shape of Training Review. In particular, higher specialty training (HST), including gastroenterology, will be shortened from 5 to 4 years. This will also incorporate general internal medicine (GIM) training. There is concern among gastroenterologists regarding how high-quality gastroenterology training will be delivered in 4 years. Methods The 2018 British Society of Gastroenterology (BSG) trainees’ survey results were used to examine the potential impact of a 4-year HST period on achieving key competencies in gastroenterology. Results 291 (49.4%) gastroenterology trainees responded. Satisfaction with gastroenterology training was high (79.6% respondents), and self-reported confidence in hepatology training was also high (84% senior respondents). However, only half (51.1%) of the respondents achieved complete colonoscopy certification by their final year of training. Comparison with the 2014 BSG trainees’ survey demonstrated that the number of endoscopy procedures achieved by trainees has reduced in sigmoidoscopy (p=0.006) and colonoscopy (p<0.001). The proportion of time spent in GIM training has increased since the last survey, with 81.8% of the respondents spending more than 25% of their time in GIM. GIM training was reported to be a key barrier to adequate gastroenterology and endoscopy training. Conclusion These data indicate significant barriers to delivering gastroenterology and endoscopy training within the current 5-year programme. Novel strategies will be required to improve the rate of progression in endoscopy training, in particular if high-quality gastroenterology HST training is to be delivered in 4 years.

1 March 2022 in Frontline Gastroenterology
Verified
Journal Article
Open access
PDF file
SSSonika Sethi
Sonika Sethi
AKAditi Kumar
Aditi Kumar
JCJennifer Clough
Jennifer Clough
SRSrivathsan Ravindran
Srivathsan Ravindran
RHRebecca Harris
Rebecca Harris
HSHelen Steed
Helen Steed
Introduction Compared with other medical specialties, there are lower numbers of female trainees and lower rates of flexible working in gastroenterology. This study aims to examine the experience of male and female trainees to understand specialty demographics and the experience of training. Methods Gastroenterology training data were obtained from the British Society of Gastroenterology (BSG) trainee surveys from 2014, 2018 and 2020, and from the Royal College of Physicians Medical Workforce unit between 2011 and 2019. Data on endoscopy measures from 2011 to 2021 were obtained from the Joint Advisory Group (JAG) on gastrointestinal endoscopy, including the JAG Endoscopy training system and the National Endoscopy Database. Data were segregated and compared by gender. Results The percentage of female gastroenterology trainees remains at around 40%, largely unchanged over the previous decade. From the BSG trainee survey, 29.5% of women have flexible working patterns compared with 2.6% of men (p<0.001), which is lower than other medical specialties. Less than half of female trainees felt confident about their job prospects once they qualify. A greater proportion of male than female trainees achieved provisional colonoscopy certification during training (55% vs 45%, p=0.005) and female trainees took longer to certify than male trainees (63 months vs 56 months, p=0.004). The total length of training time from primary medical qualification to consultancy was the same for men and women. Conclusion Changes must be addressed from a national and institutional level to address equitable access to national training programmes and equality of outcome for male and female trainees.

5 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MCMichael Colwill
Michael Colwill
SBSamantha Baillie
Samantha Baillie
JCJennifer Clough
Jennifer Clough
RPRichard Pollok
Richard Pollok
APAndrew Poullis
Andrew Poullis
SHSailish Honap
Sailish Honap
Mirikizumab is a monoclonal antibody directed against the p19 subunit of interleukin (IL)-23 to inhibit its interaction with the IL-23 receptor. IL-23 is a key cytokine involved in initiating and perpetuating the inflammatory cascade in inflammatory bowel disease (IBD). Mirikizumab is the first agent from the novel anti-IL-23p19 drug class to be licensed for ulcerative colitis and the first to present long-term endoscopic, histologic, symptomatic, and quality-of-life outcomes. More recently, the VIVID trial programme has led to the approval of mirikizumab in moderate to severe Crohn’s disease. This review explores the history of its development, discusses key immunopharmacological properties unique to the drug, and details the available clinical trials and real-world evidence supporting its use in IBD.

27 June 2020 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
JCJennie N Clough
Jennie N Clough
KHKatie L Hill
Katie L Hill
ADAlexa Duff
Alexa Duff
ESEsha Sharma
Esha Sharma
SRShuvra Ray
Shuvra Ray
MSMark A Samaan
Mark A Samaan

1 January 2015 in ACG Case Reports Journal
Verified
Journal Article
Open access
JCJennifer Clough
Jennifer Clough
RSRahul Shah
Rahul Shah
A 61-year-old woman presented with features of acute cholangitis and distal common bile duct obstruction. Histopathology from ampulla of Vater biopsy demonstrated extensive local amyloid deposition. Amyloidomas can cause local obstructive effects and have been described in the small intestine, stomach, and gallbladder. This is the second case of a discrete amyloid deposit causing extrahepatic biliary obstruction and cholangitis.